Skip to main content

Closed

TLX: Telix Pharmaceuticals Limited Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Mixed

Revenue growth+55.9% / yr

Operating margin2.1%

ROIC1.8%

Financially safe

Stretched

Debt / equity1.12×

Interest coverage0.5×

Current ratio1.43×

Telix Pharmaceuticals Limited

TLXNASDAQ·USD·Closed

Telix Pharmaceuticals Limited

TLXNASDAQ·USD·Closed

$9.89

−1.69%

$9.89

−$0.17 (1.69%)

52W Range

45thpctl

Volume

0.50×avg

Mkt Cap

3.35BUSD

P/E

-442.7TTM

Div Yield

–ann

52W Range

45thpctl

Volume

0.50×avg

Market Cap

3.35BUSD

P/E Ratio

-442.7TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings